BR9815551A - Vacina de envoltório dimérica recombinante contra infecção flaviviral - Google Patents
Vacina de envoltório dimérica recombinante contra infecção flaviviralInfo
- Publication number
- BR9815551A BR9815551A BR9815551-2A BR9815551A BR9815551A BR 9815551 A BR9815551 A BR 9815551A BR 9815551 A BR9815551 A BR 9815551A BR 9815551 A BR9815551 A BR 9815551A
- Authority
- BR
- Brazil
- Prior art keywords
- dimeric
- truncated
- protein
- wrap
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 8
- 206010057199 Flaviviral infections Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 241000725619 Dengue virus Species 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000001490 Dengue Diseases 0.000 abstract 1
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 241000255601 Drosophila melanogaster Species 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710204837 Envelope small membrane protein Proteins 0.000 abstract 1
- 241000710831 Flavivirus Species 0.000 abstract 1
- 101710145006 Lysis protein Proteins 0.000 abstract 1
- 108010076039 Polyproteins Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 229960000187 tissue plasminogen activator Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<B>VACINA DE ENVOLTóRIO DIMéRICA RECOMBINANTE CONTRA INFECçãO FLAVIVIRAL<D> A presente invenção revela e reivindica vacinas que contêm, como ingrediente ativo, uma forma dimérica secretada recombinantemente produzida de proteína truncada de envoltório flaviviral. As vacinas são capazes de elicitar a produção de anticorpos neutralizantes contra flavivírus. As formas diméricas de proteína de envoltório flaviviral truncada são formadas: 1) através da ligação direta de duas cópias tandem de 80%E em um modo de cabeça até a cauda, via uma corda flexível; 2) pela formação de um domínio de zíper de leucina através da associação homodimérica de duas hélices de zíper de leucina, cada uma fundida com o término carbóxi de uma molécula 80%E, ou 3) pela formação de um domínio de feixe de quatro hélices não covalentemente associado formado, mediante a associação de duas frações de hélice-volta-hélice,cada uma fixada ao término carbóxi de uma mólécula de 80%E. Todos os produtos são expressos como uma poliproteína que inclui prM e os produtos 80%E modificados são secretados de células Schneider 2 de Drosophila melanogaster, utilizando a seq³ência de sinal de secreção de ativador de plasminógeno de tecido humano (tPA~ L~). Os produtos secretados são, em geral, mais facilmente purificados do que aqueles expressos intracelularmente, facilitando a produção da vacina. Um modalidade da presente invenção é dirigida a uma vacina para proteção de um indivíduo contra infecção por vírus da dengue. A vacina contém, como ingrediente ativo, a forma dimérica da proteína de envoltório truncado de um sorotipo de vírus da dengue. O E truncado dimérico é secretado como uma proteína produzida recombinantemente das células eucarióticas. A vacina pode conter, ainda, porções de proteínas de E dimérico de sorotipo de vírus da dengue, adicionais, similarmente produzidas. Outras modalidade da apresente invenção é dirigida a métodos para utilizar a forma dimérica da proteína de envoltório de dengue truncada, para o diagnóstico de infecção em indivíduos em risco da doença. O diagnóstico contém, como ingrediente ativo, a forma dimérica de proteína de envoltório truncado de um sorotipo de vírus da dengue. O E truncado dimérico é secretado como uma proteína produzida recombinantemente de células eucarióticas. O diagnóstico pode conter, ainda, porções de proteínas adicionais de E dimérico de sorotipo de vírus da dengue, similarmente produzidas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90422797A | 1997-07-31 | 1997-07-31 | |
PCT/US1998/015447 WO1999006068A2 (en) | 1997-07-31 | 1998-07-27 | Recombinant dimeric envelope vaccine against flaviviral infection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9815551A true BR9815551A (pt) | 2000-10-31 |
Family
ID=25418806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9815551-2A BR9815551A (pt) | 1997-07-31 | 1998-07-27 | Vacina de envoltório dimérica recombinante contra infecção flaviviral |
Country Status (10)
Country | Link |
---|---|
US (2) | US6749857B1 (pt) |
EP (1) | EP1005363B1 (pt) |
JP (1) | JP2001511459A (pt) |
KR (1) | KR20010022452A (pt) |
AT (1) | ATE321567T1 (pt) |
AU (1) | AU752191B2 (pt) |
BR (1) | BR9815551A (pt) |
CA (1) | CA2298538A1 (pt) |
DE (1) | DE69834041T2 (pt) |
WO (1) | WO1999006068A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010022452A (ko) * | 1997-07-31 | 2001-03-15 | 추후제출 | 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신 |
AU778988B2 (en) | 1998-06-04 | 2004-12-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Nucleic acid vaccines for prevention of flavivirus infection |
US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
JP2005509399A (ja) * | 2000-11-14 | 2005-04-14 | モーフオテク・インコーポレーテツド | 遺伝的に改変された抗原の生成法 |
EP1372711A4 (en) * | 2001-03-12 | 2005-06-01 | Univ Yale | COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES |
US20050287170A1 (en) * | 2002-12-11 | 2005-12-29 | Hawaii Biotech, Inc. | Subunit vaccine against West Nile viral infection |
WO2004052293A2 (en) * | 2002-12-11 | 2004-06-24 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
US20040180058A1 (en) * | 2002-12-20 | 2004-09-16 | Shneider Alexander M. | Vaccine compositions and methods |
WO2005014627A1 (en) * | 2003-08-07 | 2005-02-17 | International Centre For Genetic Engineering And Biotechnology | Recombinant dengue multi epitope proteins as diagnostic intermediates |
WO2007034507A2 (en) * | 2005-09-20 | 2007-03-29 | International Centre For Genetic Engineering And Biotechnology | Tetravalent dengue specific domain iii based chimeric recombinant protein |
CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
CN101679954A (zh) * | 2007-04-06 | 2010-03-24 | 伊维拉根公司 | 用于活的减毒病毒的方法和组合物 |
SG157244A1 (en) * | 2008-05-15 | 2009-12-29 | Mp Biomedicals Asia Pacific Pte Ltd | Point of care test for the detection of exposure or immunity to dengue virus |
US20110150914A1 (en) * | 2008-06-09 | 2011-06-23 | La Jolla Institute For Allergy And Immunology | Compositions and methods for dengue virus (dv) treatment and vaccination |
AU2010286368B2 (en) | 2009-08-31 | 2015-09-03 | Gen-Probe Incorporated | Dengue virus assay |
US10308689B2 (en) | 2010-06-24 | 2019-06-04 | La Jolla Institute For Allergy And Immunology | Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof |
WO2012045063A2 (en) * | 2010-10-01 | 2012-04-05 | University Of Rochester | Flavivirus domain iii vaccine |
JP6018575B2 (ja) * | 2010-10-29 | 2016-11-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | デングウイルス組換えサブユニットスワクチン |
BR112015001390B1 (pt) | 2012-07-26 | 2024-04-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc | Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina |
CN105246506A (zh) | 2013-06-21 | 2016-01-13 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
GB201413086D0 (en) * | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
CR20170280A (es) | 2014-12-22 | 2017-08-21 | Merck Sharp & Dohme | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas |
JP6908299B2 (ja) * | 2016-06-06 | 2021-07-21 | メディツィニシェ ウニベルジテート ウィーン | サンプル中のフラビウイルスに特異的なIgM抗体の検出方法 |
EP3490595A4 (en) | 2016-07-27 | 2020-07-15 | Hawaii Biotech Inc. | OPTIMIZED ZIKAVIRUS ENVELOPES AND EXPRESSION THEREOF |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665710A1 (fr) | 1990-08-10 | 1992-02-14 | Pasteur Institut | Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques. |
EP0543938A4 (en) | 1990-08-14 | 1993-11-10 | Isis Pharmaceuticals, Inc. | Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
WO1992003161A1 (en) * | 1990-08-27 | 1992-03-05 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection |
ES2184869T3 (es) * | 1995-05-24 | 2003-04-16 | Hawaii Biotech Group | Vacuna sub-unitaria contra la infeccion por flavivirus. |
FR2741077B1 (fr) * | 1995-11-14 | 1998-01-23 | Pasteur Institut | Vaccin polyvalent anti-dengue |
KR20010022452A (ko) * | 1997-07-31 | 2001-03-15 | 추후제출 | 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신 |
-
1998
- 1998-07-27 KR KR1020007001037A patent/KR20010022452A/ko not_active Application Discontinuation
- 1998-07-27 AU AU85905/98A patent/AU752191B2/en not_active Expired
- 1998-07-27 EP EP98937117A patent/EP1005363B1/en not_active Expired - Lifetime
- 1998-07-27 AT AT98937117T patent/ATE321567T1/de not_active IP Right Cessation
- 1998-07-27 BR BR9815551-2A patent/BR9815551A/pt not_active Application Discontinuation
- 1998-07-27 DE DE69834041T patent/DE69834041T2/de not_active Expired - Lifetime
- 1998-07-27 WO PCT/US1998/015447 patent/WO1999006068A2/en active IP Right Grant
- 1998-07-27 JP JP2000504879A patent/JP2001511459A/ja active Pending
- 1998-07-27 CA CA002298538A patent/CA2298538A1/en not_active Abandoned
-
1999
- 1999-08-18 US US09/376,463 patent/US6749857B1/en not_active Expired - Lifetime
-
2002
- 2002-09-20 US US10/247,960 patent/US20030175304A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1005363A2 (en) | 2000-06-07 |
JP2001511459A (ja) | 2001-08-14 |
AU752191B2 (en) | 2002-09-12 |
US6749857B1 (en) | 2004-06-15 |
WO1999006068A2 (en) | 1999-02-11 |
EP1005363B1 (en) | 2006-03-29 |
DE69834041D1 (de) | 2006-05-18 |
AU8590598A (en) | 1999-02-22 |
US20030175304A1 (en) | 2003-09-18 |
ATE321567T1 (de) | 2006-04-15 |
WO1999006068A3 (en) | 1999-05-14 |
DE69834041T2 (de) | 2006-12-14 |
KR20010022452A (ko) | 2001-03-15 |
CA2298538A1 (en) | 1999-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9815551A (pt) | Vacina de envoltório dimérica recombinante contra infecção flaviviral | |
Damsky et al. | Is there a role for actin in virus budding? | |
Melero et al. | Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development | |
EP1408114B1 (de) | Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen | |
CO5690564A2 (es) | Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero | |
ES2357626T3 (es) | Lisinas mutantes de ply-gbs. | |
CN110167587A (zh) | 流感疫苗 | |
JPH09504177A (ja) | Pth活性を有する化合物およびこれをコードする組み換えdnaベクター | |
RU2018100181A (ru) | Модифицированный белок интерлейкина-7 и способы его применения | |
CN110381994A (zh) | 用于诱导针对寨卡病毒的免疫应答的核苷修饰的rna | |
KR920004572A (ko) | 재조합 진드기 알레르겐 | |
JPH11507510A (ja) | インフルエンザの新規組換え温度感受性変異体 | |
JP2005506340A5 (pt) | ||
DE60035337D1 (de) | Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken | |
US20130295093A1 (en) | Fusion constructs containing active sections of tnf ligands | |
JP2015535302A (ja) | ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異 | |
Jaramillo et al. | Translation initiation factors that function as RNA helicases from mammals, plants and yeast | |
HRP20231296T1 (hr) | Genska terapija posredovana s avv koja obnavlja gen za otoferlin | |
BR9803960A (pt) | Gene de desidrogenase de d-sorbitol. | |
KR20200129068A (ko) | Nkx3.2 단편 및 이를 함유하는 약학 조성물 | |
US11560412B2 (en) | Compositions comprising GRIM-19 therapeutics and methods of use | |
BR9812138A (pt) | Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta | |
BR0211178A (pt) | Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico | |
BR9612422A (pt) | Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais. | |
BRPI0417286A (pt) | misturas de peptìdeos ou polipeptìdeo antigênicos, peptìdeos antigênicos, polipeptìdeo antigênico, misturas antigênicas, lipopeptìdeo, mixotopo, lipomixotopo, conjugado, composições imunogênicas, vacina contra malária, uso de uma mistura, soro policlonal, anticorpo humano recombinante, usos de uma composição, medicamento, métodos e kits para o diagnóstico in vitro de malária, seqüências de nucleotìdeo, vetor de clonagem e/ou expressão recombinante, uso de um vetor de expressão vacina de dna e célula hospedeira recombinante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |